Literature DB >> 20137825

A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B.

Anthony T Tan1, Sarene Koh, Winnie Goh, Heng Yee Zhe, Adam J Gehring, Seng Gee Lim, Antonio Bertoletti.   

Abstract

BACKGROUND & AIMS: The pathogenesis of hepatic flares (HF) in patients chronically infected with hepatitis B virus (HBV) is controversial. Therefore, we studied the kinetics of innate and adaptive immune activation during HF in chronic hepatitis B.
METHODS: Soluble (IFN-alpha, IL-1beta, TNF-alpha, IL-6, IL-8, IL-10, CCL-2, CCL-3, CXCL-9, CXCL-10) and cellular (HBV-specific T cells, NK, Treg) immunological parameters were measured longitudinally (10 month-4 week intervals) in patients (n=5) who developed HF after therapy withdrawal and cross-sectionally in chronic (n=29) and acute hepatitis B patients (n=5). Hepatic expression of different chemokines was studied by co-incubating cytokines (IFN-alpha, IFN-gamma, TNF-alpha) and activated T, NK and monocytes with hepatocytes and hepatocyte-like cells.
RESULTS: A progressive increase of HBV replication precedes HF but occurs without detection of innate immune activation, with the exception of increased serum CXCL-8. Despite the absence of increased circulatory HBV-specific T or activated NK cells, HF were temporally associated with high serum levels of IFN-gamma inducible chemokines CXCL-9 and CXCL-10 (but not CCL-2 or CCL-3). CXCL-9 and CXCL-10 displayed different in vitro requirements for activation and are differentially produced in liver injury present in acute or chronic patients.
CONCLUSIONS: CXCL-9 and CXCL-10 play a major role in the development of HF. Their differential expression in acute versus chronic patients suggests the presence of different mechanisms that govern liver injury during acute and chronic hepatitis B. Copyright (c) 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20137825     DOI: 10.1016/j.jhep.2009.12.015

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  55 in total

1.  Serum cytokine levels in patients with chronic hepatitis B according to lamivudine therapy.

Authors:  Younhee Park; Yongjung Park; Kwang-Hyub Han; Hyon-Suk Kim
Journal:  J Clin Lab Anal       Date:  2011-11       Impact factor: 2.352

Review 2.  Gut microbiota modulate the immune effect against hepatitis B virus infection.

Authors:  D Xu; Y Huang; J Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-08-14       Impact factor: 3.267

3.  Chemokine antagonism in chronic hepatitis C virus infection.

Authors:  Edgar D Charles; Lynn B Dustin
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

4.  Complementarity-determining region 3 size spectratypes of T cell receptor beta chains in CD8+ T cells following antiviral treatment of chronic hepatitis B.

Authors:  Shi-Wu Ma; Yong-Yin Li; Guang-Wen Zhang; Xuan Huang; Jian Sun; Chris Li; William G H Abbott; Jin-Lin Hou
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

Review 5.  Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells.

Authors:  Barbara Rehermann
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

6.  A 3D microfluidic model for preclinical evaluation of TCR-engineered T cells against solid tumors.

Authors:  Andrea Pavesi; Anthony T Tan; Sarene Koh; Adeline Chia; Marta Colombo; Emanuele Antonecchia; Carlo Miccolis; Erica Ceccarello; Giulia Adriani; Manuela T Raimondi; Roger D Kamm; Antonio Bertoletti
Journal:  JCI Insight       Date:  2017-06-15

7.  CD8+ T-Cell Response-Associated Evolution of Hepatitis B Virus Core Protein and Disease Progress.

Authors:  George F Gao; Jingmin Zhao; Yu Zhang; Yan Wu; Mengmeng Deng; Dongping Xu; Xiaodong Li; Zhihui Xu; Jun Hu; Han Zhang; Kefang Liu; Yingze Zhao; Feng Gao; Shengli Bi; William J Liu; Songdong Meng
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

8.  Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation.

Authors:  Laura Rivino; Nina Le Bert; Upkar S Gill; Kamini Kunasegaran; Yang Cheng; Damien Zm Tan; Etienne Becht; Navjyot K Hansi; Graham R Foster; Tung-Hung Su; Tai-Chung Tseng; Seng Gee Lim; Jia-Horng Kao; Evan W Newell; Patrick Tf Kennedy; Antonio Bertoletti
Journal:  J Clin Invest       Date:  2018-01-08       Impact factor: 14.808

9.  Risk factors for liver fibrosis among human immunodeficiency virus monoinfected patients using the FIB4 index in Morocco.

Authors:  Mohamed Tahiri; Mustapha Sodqi; Fatima Ez Zahra Lahdami; Latifa Marih; Hassan Lamdini; Wafaa Hliwa; Ahd Oulad Lahcen; Wafaa Badre; Fouad Haddad; Abdelfetah Chakib; Ahmed Bellabah; Rhimou Alaoui; Kamal Marhoum El Filali
Journal:  World J Hepatol       Date:  2013-10-27

10.  Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection.

Authors:  Mayur Brahmania; Manuel Lombardero; Bettina E Hansen; Norah A Terrault; Anna S Lok; Robert P Perrillo; Steven H Belle; Adrian M Di Bisceglie; Jordan J Feld; William M Lee; Michael W Fried; Harry L A Janssen
Journal:  Clin Gastroenterol Hepatol       Date:  2019-02-08       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.